quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

HSBC, NatWest, Barclays and Nationwide hike mortgage costs

View original at uk.finance.yahoo.com
HSBC, NatWest, Barclays and Nationwide hike mortgage costs All major lenders, except Halifax, have increased mortgage rates after the Bank of England kept interest rates on hold…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Today's decision to hold rates, coupled with uncertainty over exactly when further cuts may materialise, may feel unsettling for homeowners and prospective buyers hoping for further improvements in the mortgage market.

    80% confidence
  • The BoE says further cuts are in the pipeline. Mortgage affordability is improving due to six rate cuts since summer 2024, a more relaxed lending environment, and slower house price growth.

    80% confidence
  • Homeowners with large mortgages coming off ultra-low fixed rates secured before December 2021 are most likely to feel disappointed; many five-year deals from 2021 at record lows are now expiring.

    80% confidence
  • Santander's withdrawal of 60% LTV products for first-time buyers was part of a reprice following the changes to swaps after the Bank of England held interest rates.

    80% confidence
  • An individual with a £37,500 annual income and a £30,000 deposit could borrow up to £168,375 under standard criteria. With Mortgage Boost adding a second applicant earning £37,500, combined borrowing could reach £270,000.

    80% confidence
  • We've been used to fixed rates dropping, and we won't see rates rocket, but the more lenders nudge prices up, the more others will follow – that growing momentum will increase rates across the board.

    80% confidence
  • Further interest rate cuts are in the pipeline.

    80% confidence
  • Some major high-street lenders have upped mortgage rates in recent weeks; borrowers are in a much better place than in 2023 when average two- and five-year fixed rates were comfortably above 6%.

    80% confidence
  • Borrowers holding off for lower rates are probably going to get a sharp reminder that they're not always possible.

    80% confidence
  • The average five-year fixed deal came in at 4.98%, unchanged from the previous week.

    80% confidence
  • The average rate for a two-year fixed mortgage came in at 4.53% this week, up from the previous 4.49%.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com